Nal-IRI/FL

DRUG2 trials

Sponsors

SONIRE Therapeutics Inc.

Conditions

Pancreatic CancerUnresectable Pancreatic Cancer

Early Phase 1

Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)

RecruitingNCT07033689

SONIRE Therapeutics Inc.Pancreatic Cancer

Start: 2026-01-05End: 2027-03-01Target: 10Updated: 2026-04-03

Unknown Phase

A Study of Suizenji in Patients With Unresectable Pancreatic Cancer

Active, not recruitingNCT05601323

SONIRE Therapeutics Inc.Unresectable Pancreatic Cancer

Start: 2023-01-31End: 2027-05-31Target: 90Updated: 2026-03-16